New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors
October 17 2019 - 5:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today that the
results of a preclinical study conducted by Nestlé were published
last month in the journal Nature Communications, a peer-reviewed
open access scientific journal published by the Nature Publishing
Group. The study investigated the impact on the liver when its
cells lose the ability to use the nutrient nicotinamide riboside
(NR). The preclinical study concluded that the tissue’s natural
ability to utilize NR is important for maintaining resilience
during periods of metabolic stress such as a high-fat diet. It is
also the first study to show the physiological consequences that
arise when cells lose the ability to use NR.
In December 2018, ChromaDex entered into a
license and supply agreement for NIAGEN® (nicotinamide riboside)
with Nestlé Health Science, a global leader pioneering quality
science-based nutritional health solutions.
The body uses NR to boost nicotinamide adenine
dinucleotide, or NAD, a molecule found in cells that powers
metabolism and helps cells be more resilient in the face of
metabolic stress. Recent studies have shown preclinically that NR
has unique NAD-boosting properties in the liver and physiological
benefits for aged blood stem cells. This new study provides
additional evidence that NR is physiologically distinct from other
NAD precursors and may play a unique role in maintaining cellular
health and resiliency in the face of metabolic stress.
“This is an important study by Dr. Canto and our
partners at Nestlé,” said Dr. Matthew Roberts, Chief Scientific
Officer at ChromaDex. “The findings highlight an emerging area of
research in the physiological uniqueness of NR as an NAD precursor
and furthers our understanding of the role NR plays in liver
health.”
Dr. Carles Cantó, scientist at Nestlé, who is
the corresponding author of the study said, “This is the first
paper suggesting a functional uniqueness of NR that cannot be
mimicked by other precursors and indicates that there might exist
true situations of NR deficit and not simply NAD+ deficit.”
For additional information on the science
supporting NR and Niagen, please visit www.chromadex.com.
About ChromaDex:ChromaDex Corp.
is a science-based integrated nutraceutical company devoted to
improving the way people age. ChromaDex scientists partner with
leading universities and research institutions worldwide to uncover
the full potential of NAD and identify and develop novel,
science-based ingredients. Its flagship ingredient, NIAGEN®
nicotinamide riboside, sold directly to consumers as TRU NIAGEN®,
is backed with clinical and scientific research, as well as
extensive IP protection. TRU NIAGEN® is helping the world AGE
BETTER®. ChromaDex maintains a website at www.chromadex.com to
which ChromaDex regularly posts copies of its press releases as
well as additional and financial information about the Company.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2018, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
ChromaDex Media Contact:Alex Worsham, Senior
Director of Global Corporate Communications310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Vice President of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024